Cargando…

Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting

Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesquita, André, Rocha-Castro, Carlos, Guimarães, Daniela, Costa, Joana, Soutinho, Joana, Taveira-Gomes, Tiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566079/
https://www.ncbi.nlm.nih.gov/pubmed/36232149
http://dx.doi.org/10.3390/ijerph191912847
_version_ 1784809053623418880
author Mesquita, André
Rocha-Castro, Carlos
Guimarães, Daniela
Costa, Joana
Soutinho, Joana
Taveira-Gomes, Tiago
author_facet Mesquita, André
Rocha-Castro, Carlos
Guimarães, Daniela
Costa, Joana
Soutinho, Joana
Taveira-Gomes, Tiago
author_sort Mesquita, André
collection PubMed
description Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended to characterize the prescribed treatments evaluating effectiveness, adverse outcomes and compliance in a real-world setting in a primary care unit. A prospective multicenter observational cohort study was developed in five primary care units of Braga, Portugal. Patients diagnosed with H. pylori infection from August 2021 to January 2022 were included. Data were collected by interview (3 weeks after treatment) and review of medical records. Comparison between two groups of treatment and multivariable analysis was conducted. We estimated 13.4 cases per 1000 adults/year from 185 diagnoses. Therapy with bismuth was the most prescribed (83.8%) with a 96.7% eradication rate. There were no significant differences between treatments. Adverse events were reported in 73.8% of inquiries and female patients were associated with higher reports of nausea (p = 0.03) and metallic taste (p = 0.02). Both eradication schemes were effective and secure. The higher rate of adverse outcomes should be validated but it could influence the debate concerning treating all patients, especially in low gastric cancer-prevalence regions.
format Online
Article
Text
id pubmed-9566079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95660792022-10-15 Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting Mesquita, André Rocha-Castro, Carlos Guimarães, Daniela Costa, Joana Soutinho, Joana Taveira-Gomes, Tiago Int J Environ Res Public Health Article Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended to characterize the prescribed treatments evaluating effectiveness, adverse outcomes and compliance in a real-world setting in a primary care unit. A prospective multicenter observational cohort study was developed in five primary care units of Braga, Portugal. Patients diagnosed with H. pylori infection from August 2021 to January 2022 were included. Data were collected by interview (3 weeks after treatment) and review of medical records. Comparison between two groups of treatment and multivariable analysis was conducted. We estimated 13.4 cases per 1000 adults/year from 185 diagnoses. Therapy with bismuth was the most prescribed (83.8%) with a 96.7% eradication rate. There were no significant differences between treatments. Adverse events were reported in 73.8% of inquiries and female patients were associated with higher reports of nausea (p = 0.03) and metallic taste (p = 0.02). Both eradication schemes were effective and secure. The higher rate of adverse outcomes should be validated but it could influence the debate concerning treating all patients, especially in low gastric cancer-prevalence regions. MDPI 2022-10-07 /pmc/articles/PMC9566079/ /pubmed/36232149 http://dx.doi.org/10.3390/ijerph191912847 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mesquita, André
Rocha-Castro, Carlos
Guimarães, Daniela
Costa, Joana
Soutinho, Joana
Taveira-Gomes, Tiago
Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title_full Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title_fullStr Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title_full_unstemmed Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title_short Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
title_sort multicentric study to assess helicobacter pylori incidence, patient reported adverse events, compliance and effectiveness, in real-world setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566079/
https://www.ncbi.nlm.nih.gov/pubmed/36232149
http://dx.doi.org/10.3390/ijerph191912847
work_keys_str_mv AT mesquitaandre multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting
AT rochacastrocarlos multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting
AT guimaraesdaniela multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting
AT costajoana multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting
AT soutinhojoana multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting
AT taveiragomestiago multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting